User Name:


remember me

Forgot your password?

Not a member?

Join Now

News Topic - Merck

RSS feedDisplaying articles 1 - 10 of most recent articles

Photo from Yahoo! News
Merck, Pfizer drug combo extends kidney cancer survival: study Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released inter
Yahoo! News | 18 hours, 39 minutes ago | comment? | recommend
Photo from Yahoo! News
Merck to further study Keytruda in prostate cancer after early success (Reuters) - Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial. The interim findi
Yahoo! News | Feb 14, 2019 2:51 PM [GMT] | comment? | recommend
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
Yahoo! News | Feb 12, 2019 3:10 PM [GMT] | comment? | recommend
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Yahoo! News | Feb 12, 2019 2:12 PM [GMT] | comment? | recommend
Photo from Yahoo! News
Merck, Pfizer combo treatment boosts kidney cancer survival Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemo
Yahoo! News | Feb 12, 2019 01:02 AM [GMT] | comment? | recommend
FDA Accepts sBLA and Grants Priority Review for BAVENCIO (avelumab) Plus INLYTA (axitinib) for the Treatment of Advanced Renal Cell Carcinoma ROCKLAND, Massachusetts and NEW YORK, Feb. 11, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FD
PR Newswire | Feb 11, 2019 10:44 PM [GMT] | comment? | recommend
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Yahoo! News | Feb 8, 2019 12:51 PM [GMT] | comment? | recommend
Photo from Yahoo! News
Prior dengue infection may protect against Zika: study The finding, published in the journal Science, could have implications for approved and experimental dengue vaccines by Sanofi, Takeda Pharmaceutical, Merck & Co and Brazil's Butantan Institute, they said. It was based on tests of blood samples from a lon
Yahoo! News | Feb 7, 2019 7:09 PM [GMT] | comment? | recommend
$4.2B deal: GSK and Merck KGaA to develop cancer immunotherapy GlaxoSmithKline is teaming up with Merck KGaA of Germany in a multibillion-deal to jointly develop an experimental immunotherapy treatment for multiple difficult-to-treat cancers. Under the terms of the agreement, GSK (NYSE: GSK) will make an $342.8 milli
Triangle Business Journal | Feb 6, 2019 1:10 PM [GMT] | comment? | recommend article from Raleigh, North Carolina
Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.
Yahoo! News | Feb 6, 2019 12:47 PM [GMT] | comment? | recommend